









Markets
/
Stocks
/
nasdaq-spry
/

ARS Pharmaceuticals Inc

SPRY

9.720USD

-0.080-0.82%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

959.34MMarket Cap

LossP/E TTM



ARS Pharmaceuticals Inc

9.720

-0.080-0.82%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ARS Pharmaceuticals Inc

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ARS Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

45 / 505

Overall Ranking

128 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

32.571

Target Price

+232.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ARS Pharmaceuticals Inc Highlights

StrengthsRisks

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 6674.24% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 89.15M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is -20.08, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 96.00M shares, decreasing 10.83% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 105.00K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 7.31, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.72M, representing a year-over-year increase of 3043.40%, while its net profit experienced a year-over-year increase of 258.60%.

Score

Industry at a Glance

Previous score

7.31

Change



Financials

5.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.86

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

ARS Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 6.91, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -20.08, which is -998.18% below the recent high of 180.34 and -477.61% above the recent low of -115.98.

Score

Industry at a Glance

Previous score

6.91

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 45/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 9.14, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for ARS Pharmaceuticals Inc is 32.00, with a high of 40.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

9.14

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

32.571

Target Price

+232.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

ARS Pharmaceuticals Inc

SPRY

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

argenx SE

ARGX

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 6.66, which is lower than the Biotechnology & Medical Research industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 11.23 and the support level at 8.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.79

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.387

Neutral

RSI(14)

32.331

Neutral

STOCH(KDJ)(9,3,3)

30.717

Neutral

ATR(14)

0.461

High Vlolatility

CCI(14)

-42.753

Neutral

Williams %R

71.367

Sell

TRIX(12,20)

-1.503

Sell

StochRSI(14)

84.957

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

9.726

Sell

MA10

9.712

Buy

MA20

10.077

Sell

MA50

13.638

Sell

MA100

14.552

Sell

MA200

13.488

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 97.76%, representing a quarter-over-quarter decrease of 4.61%. The largest institutional shareholder is The Vanguard, holding a total of 3.25M shares, representing 3.29% of shares outstanding, with 6.77% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

10.86M

OrbiMed Advisors, LLC

8.29M

Deerfield Management Company, L.P.

10.51M

Lowenthal (Richard E)

6.83M

-14.34%

Pratik Shah Living Trust

4.82M

Tanimoto (Sarina)

4.57M

-10.85%

SR One Capital Management, LP

4.01M

BlackRock Institutional Trust Company, N.A.

3.88M

-6.63%

AllianceBernstein L.P.

3.92M

+1.08%

The Vanguard Group, Inc.

Star Investors

3.48M

+0.68%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 5.08, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.